{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:21:17Z","timestamp":1754162477768,"version":"3.41.2"},"reference-count":6,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s550970","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T07:20:14Z","timestamp":1753860014000},"page":"535-536","source":"Crossref","is-referenced-by-count":0,"title":["Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter]"],"prefix":"10.2147","volume":"Volume 17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9289-5977","authenticated-orcid":true,"given":"Niodita","family":"Gupta-Werner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Goble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Slavcev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/CEOR.S501404","volume":"17","author":"Shah","year":"2025","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Karlin L, Benboubker L, et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the MajesTEC-1 study. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL; 2023.","DOI":"10.1016\/S2152-2650(23)01410-6"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41408-024-01160-1","volume":"14","author":"van de Donk","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/105283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/105283","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T07:20:16Z","timestamp":1753860016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/economic-impact-of-elranatamab-for-treatment-of-patients-with-relaps-2-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":6,"URL":"https:\/\/doi.org\/10.2147\/ceor.s550970","relation":{},"ISSN":["1178-6981"],"issn-type":[{"type":"electronic","value":"1178-6981"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}